Status:

COMPLETED

CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision

Lead Sponsor:

Sanofi

Conditions:

Rectal Neoplasms

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Primary objective: * Pathological complete response (ypT0N0) rate Secondary objectives: * Histopathological R0 resection rate * Pathological downstaging (ypT0-T2N0) rate * One month surgical compli...

Eligibility Criteria

Inclusion

  • Histologically proven adenocarcinoma of the rectum (Tumour ≤ 12 cm from the anal verge)
  • No evidence of distant spread
  • No prior therapy for chemotherapy or radiation therapy for rectal cancer
  • Patient considered locally advanced by MRI:
  • Tumour beyond mesorectal fascia, or
  • Tumour ≤ 2mm from mesorectal fascia, or
  • T3 tumour \< 5cm from anal verge
  • For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception
  • No peripheral neuropathy \> grade1
  • ECOG PS ≤ 2
  • ANC \> 1,500 x 10\^9/L
  • Platelets \> 100,000 x 10\^9/L
  • Creatinine \< 1.5 x IULN
  • Bilirubin \< 1.5 IULN
  • SGPT (ALT) \< 2.5 IULN
  • No pre-existing condition which would deter chemoradiotherapy
  • No uncontrolled diarrhoea or fecal incontinence
  • No significant small bowel (\> 200cc or 6X6X6cm) delineated within the radiation fields
  • No other serious uncontrolled concomitant illness
  • Informed consent signed
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Exclusion

    Key Trial Info

    Start Date :

    July 1 2003

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 1 2007

    Estimated Enrollment :

    87 Patients enrolled

    Trial Details

    Trial ID

    NCT00174616

    Start Date

    July 1 2003

    End Date

    November 1 2007

    Last Update

    December 7 2009

    Active Locations (7)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (7 locations)

    1

    Sanofi-Aventis Administrative Office

    Diegem, Belgium

    2

    Sanofi-Aventis Administrative Office

    Paris, France

    3

    Sanofi-Aventis Administrative Office

    Frankfurt, Germany

    4

    Sanofi-Aventis Administrative Office

    Milan, Italy

    CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision | DecenTrialz